SLEDAI-2K for a 30-day window.
The aim of our study was to determine whether the SLEDAI-2K calculated using a timeframe of 30 days prior to a visit for clinical and laboratory variables was equivalent to the prescribed 10-day period. One hundred forty nine consecutive lupus patients seen over 9 weeks at the University of Toronto Lupus Clinic enrolled. The SLEDAI-2K score was completed twice, for a 10- and 30-day window. Forty patients had a classic SLEDAI-2K activity score of 0 and 109 patients had varying levels of disease activity ranging from 1 to 31. In all but one patient, there was agreement between the SLEDAI-2K 10 and 30 days. Thus SLEDAI-2K 30 days is similar to SLEDAI-2K 10 days, both in patients in remission and with a spectrum of disease activity levels. SLEDAI-2K 30 days may now be used to describe disease activity over the previous 30 days.
Touma
Z
Z
University of Toronto Lupus Clinic, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada.
Urowitz
M B
MB
Gladman
D D
DD
D000328:Adult; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013997:Time Factors